Rise in demand for advanced therapeutics, increase in product approval and product development and rise in adoption of strategies by key market players drive the growth of the global plasma protein therapeutics market
PORTLAND, Ore., April 12, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Plasma Protein Therapeutics Market by product type (Immunoglobulin, Albumins, Plasma Derived Factor VIII and Others), by Application (Hemophilia, Idiopathic Thrombocytopenic purpura, Primary Immunodeficiency Disorder and Others) by End User (Hospital and Others): Global Opportunity Analysis and Industry Forecast, 2022-2031". According to the report, the global plasma protein therapeutics generated $26,527.82 million in 2021, and is anticipated to generate $44,296.78 million by 2031, witnessing a CAGR of 5.2% from 2022 to 2031.
Download Free Sample Report: https://www.alliedmarketresearch.com/request-sample/13057
Prime determinants of growth
Rise in adoption of key strategies by key players, increase in number of product approvals and product launch and further rise in demand of advanced therapeutics owing to rise in autoimmune disorders and other chronic diseases and surge in demand of effective treatment solutions drive the growth of the global plasma protein therapeutics market. However, strict regulations for handling plasma protein products are expected to restrict the growth of the plasma protein therapeutics market. On the contrary, the growing technological advancement are expected to offer remunerative opportunities for expansion of the plasma protein therapeutics market during the forecast period.
Report coverage & details:
Report Coverage |
Details |
Forecast Period |
2022–2031 |
Base Year |
2021 |
Market Size in 2021 |
$26,527.82 million |
Market Size in 2031 |
$44,296.78 million |
CAGR |
5.2 % |
No. of Pages in Report |
389 |
Segments covered |
Product type, Application, End User and Region. |
Drivers |
Rise in demand for advanced therapeutics Rise in adoption of strategies by key market players Increase in product approval and product development |
Opportunities |
Technological advancements |
Restraints |
Strict regulation for handling plasma protein products |
Covid-19 Scenario
- Due to the COVID-19 pandemic and the subsequent global lockdowns, the plasma protein therapeutics market faced a downturn.
- However, after the pandemic restrictions are lifted, it is expected that the supply of plasma will increase, leading to an increase in the production and availability of plasma-derived therapies.
The immunoglobulin segment to maintain its leadership status throughout the forecast period
Based on product type, the immunoglobulin segment held the highest market share in 2021, accounting for more than half of the global plasma protein therapeutics market revenue, and is and is projected to manifest the highest CAGR of 5.6% during forecast period, owing to increase in availability of innovative immunoglobulin products and developments in therapeutic administration, such as the subcutaneous immunoglobulin products.
The hemophilia segment to maintain its leadership status throughout the forecast period
Based on application, the Hemophilia segment held the highest market share in 2021, accounting for nearly three-fifthof the global plasma protein therapeutics market revenue, and is estimated to maintain its leadership status throughout the forecast period, owing to the rise in people diagnosed with hemophilia and increase in availability of plasma protein therapeutics options for hemophilia. However, the primary immunodeficiency disorder segment is projected to manifest the highest CAGR of 5.8% from 2022 to 2031, owing to rise in awareness regarding use of plasma protein therapeutics for the treatment of the primary immunodeficiency and their high prevalence.
Procure Complete Report (220 Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.alliedmarketresearch.com/checkout-final/plasma-protein-therapeutics-market
The hospital segment to maintain its lead position during the forecast period
Based on end user, the hospital segment accounted for the largest share in 2021, contributing around three-fourth of the global plasma protein therapeutics market revenue, owing to increase in number of patient visits in hospitals suffering from autoimmune conditions such as hemophilia and ease of access of protein therapeutics in hospital. However, the others segment is expected to portray the largest CAGR of 5.6% from 2022 to 2031, and is projected to maintain its lead position during the forecast period. This is owing to cost effectiveness, and ease of scheduling visits.
North America to maintain its dominance by 2031
Based on region, North America held the highest market share in terms of revenue in 2021, accounting for nearly half of the global plasma protein therapeutics market revenue, owing to rise in investments for plasma protein therapeutics research, increase in cases of rare diseases and high prevalence of immunological disorders. However, the Asia-Pacific region is expected to witness the fastest CAGR of 6.0% from 2022 to 2031, and is likely to dominate the market during the forecast period, owing to enhancements in healthcare facilities and improvements in patient awareness about plasma protein therapeutics.
Leading Market Players: -
- Octapharma Ag
- Grifols, S.A.
- Baxter International Inc.
- Adma Biologics Inc
- Bio Products Laboratory Ltd
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Kedrion, Spa
- Taibang Biological Group Co., Ltd
- Bayer AG
The report provides a detailed analysis of these key players of the global plasma protein therapeutics market. These players have adopted different strategies such as new product launches, acquisition, agreements, product approval and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Trending Reports in Healthcare Industry (Book Now with 10% Discount):
Endoscopic Ultrasound (EUS) Market by Product (Endoscopes, Ultrasound probes, Ultrasonic processors, Imaging system, Needles, Accessories), by Application (Oncology, Pancreatic conditions, Others), by End user (Hospitals, Ambulatory surgery centers and Clinics, others): Global Opportunity Analysis and Industry Forecast, 2021-2031
Skin Cancer Treatment Market by Type (Melanoma, Non-Melanoma), by Therapy (Immunotherapy, Targeted Therapy, Chemotherapy), by Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
Behavioral Health Market by Disorder (Alcohol Use Disorders, Substance Abuse Disorders, Eating Disorders, ADHD, Others), by Service (Emergency Mental Health Services, Outpatient Counselling, Home-based Treatment Services, Inpatient Hospital Treatment Services, Other Services), by Age Group (Pediatric, Adult, Geriatric): Global Opportunity Analysis and Industry Forecast, 2021-2031
Laser Hair Removal Market by Type (Alexandrite laser hair removal, Diode laser hair removal, Others), by Gender (Male, Female), by Age group (13 to 29, 30 to 54, 55 to 69), by End User (Hospitals, Clinic, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
Bone Void Fillers Market by Type (Demineralized bone matrix, Calcium phosphate bone graft substitute, Collagen Matrix, Others), by Form (Gel and Putty, Granules, Others), by Application (Spine fusion, Bone fracture, Others), by End User (Hospital, Specialty Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
SOURCE Allied Market Research
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article